ArticleACS omega2026
Development of Scaffold Based on Buriti Oil and PEG-400 at Low Temperature.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone mass loss due to trauma or disease is a growing problem, requiring biocompatible and structurally stable materials for bone regeneration. In this study, interconnected porous scaffolds were developed from monoacylglyceride (MAG) derived from buriti oil (OB), combined with PEG-400, to examine the feasibility of MAG/PEG-400 as a biomedical scaffold to overcome the disadvantages of traditional implants. Fourier transform infrared (FTIR) analyses confirmed the formation of the scaffolds (Sc1 and Sc2), and scanning electron microscopy (SEM) images revealed porous structures with aver-age pore sizes of 248 and 258 μm, ideal for bone regeneration. The presence of β-carotene in the scaffolds was evidenced by UV-vis, and their thermal stability exceeded 200 °C. MTT assays indicated cell viability comparable to the control, while hemolysis tests revealed higher hemolytic activity in Sc1, possibly due to PEG-400. These OB-based polyurethanes stand out as a promising innovation, providing a suitable cellular microenvironment for bone regeneration and representing a significant contribution to sustainable biomaterials in tissue engineering (TE).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.